Lipanthyl Penta/Lipanthyl Supra Dosage/Direction for Use

Posology: Adults: Lipanthyl Penta: The recommended dose is one tablet containing 145 mg fenofibrate taken once daily. Patients currently taking one 200mg capsule or one 160mg tablet can be changed to one 145 mg fenofibrate tablet without further dose adjustment.
For hyperlipidaemia indications, response to therapy should be monitored by determination of serum lipid values. If an adequate response has not been achieved after several months (e.g. 3 months), complementary or different therapeutic measures should be considered.
If a patient needs fenofibrate for both hyperlipidemia and diabetic retinopathy indications, only one tablet of fenofibrate 145 mg per day should be taken.
Lipanthyl Supra: Response to therapy should be monitored by determination of serum lipid values (total cholesterol, LDL-Cholesterol, triglycerides), if an adequate response has not been achieved after several months (e.g. 3 months) complementary or different therapeutic measures should be considered.
Posology: Adults: The recommended dose of LIPANTHYL SUPRA 160 mg tablets is one tablet taken once daily. Patients currently taking one 160 mg tablet can be changed to one 145 mg fenofibrate tablet without further dose adjustment.
Special Populations: Geriatric population: In elderly patients, without renal impairment, the usual adult dose is recommended.
Renal impairment: Dosage reduction is required in patients with renal impairment.
In moderate chronic kidney disease (creatinine clearance 30 to 59 mL/min), and if a low dose is available, start with one capsule of 100 mg standard or 67 mg micronized once daily.
If no low dose is available, then fenofibrate is not recommended.
In patients with severe (Lipanthyl Penta)/chronic (Lipanthyl Supra) kidney disease (creatinine clearance <30 ml/min), fenofibrate is contraindicated.
Hepatic impairment: LIPANTHYL PENTA 145/LIPANTHYL SUPRA 160 is not recommended for use in patients with hepatic impairment due to the lack of data.
Paediatric population: The safety and efficacy of fenofibrate in children and adolescents younger than 18 years has not been established. No data are available. Therefore the use of fenofibrate is not recommended in paediatric subjects under 18 years.
Method of administration: Lipanthyl Penta: LIPANTHYL PENTA 145, film-coated tablet may be given at any time of the day, with or without food (see Pharmacology: Pharmacokinetics under Actions). Tablet should be swallowed whole with a glass of water.
Lipanthyl Supra: Tablets should be swallowed whole during a meal.